Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

Benzinga Newsdesk www.benzinga.com Positive 82.8%

Neg 0% Neu 0% Pos 82.8%

Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.